Femara Tablets (Letrozole)

Adult dose

○ Adults and older adults : The recommended dose is 2.5 mg of letrozole orally once daily, regardless of meals. If a dose is missed, take it as soon as remembered. However, if it is close to the time for the next dose, skip the missed dose and take the next dose at the scheduled time. Do not take a double dose to make up for a missed dose, and do not exceed the recommended dose of 2.5 mg. In patients with metastatic disease, treatment should be continued until progression of the cancer is confirmed. For adjuvant therapy and extended adjuvant therapy following adjuvant tamoxifen therapy, treatment may be continued for 5 years. If cancer recurs during treatment, discontinue the medicine (for extended adjuvant therapy following adjuvant tamoxifen therapy, the optimal treatment duration associated with long-term use has not been established.). ○ Patients with hepatic impairment : The blood concentration of this medicine is slightly increased in patients with moderate hepatic impairment due to cirrhosis, but no dosage adjustment is necessary in patients with mild to moderate hepatic impairment. However, if this medicine is used in patients with severe hepatic impairment (Child-Pugh score C), continuous and careful supervision is required. ○ Patients with renal impairment : No dosage adjustment is necessary in patients with renal impairment and creatinine clearance of 10 mL/min or greater.

This medication should not be used in certain patients. Individuals allergic to this drug or its components, premenopausal women, women who are pregnant or may become pregnant, and nursing mothers should not take this medication. Caution must be exercised when prescribing this medication to patients with severely impaired kidney function or severe liver dysfunction. Additionally, patients with a history of osteoporosis or high fracture risk, as well as women whose menopausal status is uncertain should consult a specialist before taking this medication. Various side effects may occur while taking this medication. Common symptoms often manifest due to decreased estrogen levels, including facial flushing, arthralgia, fatigue, nausea, etc. Adverse reactions such as hypercholesterolemia, hair loss, dry skin, thrombosis, and osteoporosis have also been reported. This drug is primarily metabolized in the liver, so patients with compromised liver function need to exercise caution and should promptly notify healthcare professionals if symptoms of liver dysfunction appear. While driving or operating machinery, one must be cautious as there may be fatigue or dizziness. Furthermore, this medication may interact with other drugs, so if currently taking any medications, it is essential to inform the physician or pharmacist. Women who are pregnant or breastfeeding should not take this medication, and women who may become pregnant should use sufficient contraception. The safety and efficacy of this drug in children under 17 years of age have not been established. There is no special dose adjustment needed for the elderly, but caution is required as there may be a higher risk of fractures. In the case of overdose, as there is no specific antidote, proper treatment and monitoring based on symptoms are necessary. This medication should be kept out of the reach of children and stored in its original container for safety.

• Urinary tract infection
• tumor pain
• leukopenia
• anaphylaxis-like reactions
• hypercholesterolemia
• loss of appetite
• increased appetite
• depression
• anxiety
• hypersensitivity

This medication should be stored in a tightly sealed container that is well-ventilated and kept in a cool place below 30 degrees Celsius. It is also important to store it in an environment free from excessive moisture.

Appearance

Dark yellow round film-coated tablets

Package unit

30 tablets (10 tablets/PTP packaging × 3)